Today prostate cancer screening is done using a prostate-specific antigen (PSA) blood test, followed by a prostate biopsy if PSA levels are elevated.
But research shows that PSA levels are often inaccurate, resulting in overdiagnosis and unnecessary biopsies. Not to mention that prostate biopsies may have side effects such as bleeding, infection, urinary issues, and erectile dysfunction1.
We’re also building Artificial Intelligence technology, the Ezra AI, that’s designed to assist radiologists in their analysis and make them more accurate and productive. After further study of our AI technology, we plan to seek FDA clearance and make the Ezra AI available to radiologists. Our aim is simple: To develop the next generation prostate cancer screening technology.
Ezra is currently invite-only but you can request an invite by clicking the link below.
We have partnered with Lenox Hill Radiology, one of the leading medical imaging networks in New York.
You will receive your Ezra report within 48 hours from having your MRI scan done.
“MRI is an effective medical imaging modality for prostate cancer detection”
MRI is an effective medical imaging modality for prostate cancer detection. It’s also non-intrusive and fast, so it has the potential of becoming the new standard of care for prostate cancer screening.
"Ezra's screening protocol is an incredibly promising alternative to the current diagnostic paradigm."
PSA tests are inaccurate and often result in unnecessary prostate biopsies. MRI provides an alternative that is fast, accurate and with limited side effects, while MRI-guided biopsies can increase the number of clinically significant cancers identified. Ezra's screening protocol is an incredibly promising alternative to the current diagnostic paradigm.
“AI has the potential of making radiologists more accurate and efficient.”
AI has the potential of making radiologists more accurate and efficient. Once it is cleared by the FDA, Ezra’s AI technology has the potential to be a faster, more affordable way to screen for prostate cancer.